Table 5.
Consistency of individual patient’s IL‐2, IFN‐γ, and/or IL‐10 responses to active peptides using pooled plasma
| Peptide | Sequence * | Peptide response ‐ ratio of peptide signal to negative control signal (>1.5 indicated in red) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL‐2 Participant | IFN‐γ Participant | IL‐10 Participant | |||||||||||||||||
| 101 | 102 | 103 | 104 | 105 | 106 | 101 | 102 | 103 | 104 | 105 | 106 | 101 | 102 | 103 | 104 | 105 | 106 | ||
| Blood collected at baseline | |||||||||||||||||||
| 8 | QQFPGQQQPFPPQQ | 1.5 | 0.4 | 0.6 | 1.1 | 0.8 | 1.1 | 1.1 | 1.2 | 0.9 | 1.3 | 0.9 | 0.9 | 2.9 | 0.3 | 0.9 | 1.0 | 1.3 | 1.0 |
| 15 | LQLQPFPQPQLPYP | 1.6 | 0.4 | 5.9 | 1.0 | 1.0 | 0.9 | 1.1 | 0.9 | 2.4 | 1.1 | 0.8 | 0.8 | 1.1 | 0.8 | 0.8 | 1.0 | 0.9 | 0.9 |
| 16 | PFPQPQLPYPQPQL | 1.4 | 0.8 | 4.3 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.3 | 1.0 | 1.0 | 0.9 | 1.5 | 0.5 | 1.0 | 1.0 | 0.9 | 0.9 |
| 17 | PQLPYPQPQLPYPQ | 2.4 | 0.5 | 15.9 | 0.9 | 1.0 | 0.9 | 1.3 | 1.1 | 1.3 | 1.0 | 1.0 | 0.8 | 1.2 | 0.7 | 1.1 | 1.0 | 1.2 | 0.8 |
| 18 | YPQPQLPYPQPQLP | 1.7 | 0.7 | 2.8 | 1.0 | 1.0 | 0.7 | 1.0 | 1.0 | 1.1 | 1.0 | 1.1 | 0.8 | 1.1 | 0.6 | 1.1 | 1.0 | 1.0 | 0.8 |
| 21 | PQPFRPQQPYPQSQ | 1.3 | 0.6 | 5.7 | 1.0 | 2.6 | 0.7 | 1.0 | 0.9 | 1.1 | 1.1 | 0.8 | 1.0 | 0.9 | 0.6 | 1.0 | 1.0 | 0.7 | 0.7 |
| 36 | DVVLQQHSIAYGSS | 1.3 | 0.5 | 0.9 | 0.9 | 0.7 | 0.7 | 1.0 | 0.5 | 1.0 | 1.0 | 0.8 | 0.4 | 2.0 | 19.5 | 0.8 | 1.0 | 1.1 | 1.3 |
| 46 | RCQAIHNVVHAIIL | 1.5 | 1.1 | 1.0 | 0.8 | 0.8 | 0.8 | 1.1 | 0.6 | 0.8 | 1.2 | 0.9 | 0.3 | 1.0 | 0.7 | 0.9 | 1.0 | 0.9 | 0.9 |
| 47 | IHNVVHAIILHQQQ | 1.8 | 1.1 | 1.0 | 1.1 | 1.0 | 2.6 | 1.3 | 0.2 | 1.1 | 1.3 | 0.8 | 0.6 | 7.7 | 7.8 | 1.2 | 0.9 | 1.2 | 1.1 |
| 83 | LQLQPFPQPELPYP | 1.4 | 1.0 | 11.9 | 0.7 | 1.2 | 0.8 | 1.0 | 0.8 | 1.5 | 1.0 | 1.0 | 1.1 | 1.1 | 0.7 | 1.1 | 0.8 | 1.0 | 0.8 |
| 84 | PFPQPELPYPQPQL | 1.3 | 0.7 | 17.4 | 0.7 | 3.6 | 0.9 | 1.0 | 0.9 | 1.3 | 1.1 | 1.2 | 1.0 | 0.9 | 0.5 | 1.0 | 0.9 | 0.9 | 0.7 |
| 85 | PELPYPQPELPYPQ | 1.2 | 0.8 | 52.7 | 1.0 | 1.7 | 2.0 | 1.0 | 1.0 | 5.3 | 1.1 | 1.1 | 1.2 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 |
| 86 | YPQPELPYPQPQLP | 1.8 | 0.8 | 9.7 | 1.1 | 5.5 | 0.9 | 1.1 | 0.9 | 2.1 | 1.2 | 1.1 | 0.9 | 1.1 | 0.8 | 0.8 | 1.2 | 1.1 | 0.9 |
| 89 | PQPFRPEQPYPQSQ | 1.5 | 1.1 | 19.7 | 0.8 | 11.5 | 0.8 | 1.0 | 1.4 | 1.5 | 1.0 | 2.6 | 0.7 | 1.3 | 0.8 | 0.9 | 0.9 | 1.0 | 0.8 |
| 91 | SQPQYSQPEQPISQ | 1.5 | 0.9 | 3.7 | 0.8 | 0.9 | 0.8 | 1.1 | 1.1 | 0.8 | 1.1 | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 1.1 | 0.9 | 0.8 |
| Blood collected on Day 6 after commencing gluten challenge | |||||||||||||||||||
| 8 | QQFPGQQQPFPPQQ | 0.7 | 2.1 | 0.9 | 1.1 | 0.7 | 0.8 | 1.1 | 1.3 | 0.9 | 1.0 | 1.2 | 0.9 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 |
| 15 | LQLQPFPQPQLPYP | 11.5 | 2.6 | 50.3 | 1.0 | 26.8 | 4.1 | 1.4 | 0.9 | 6.8 | 0.9 | 5.3 | 0.9 | 1.1 | 1.1 | 1.5 | 0.8 | 1.1 | 1.1 |
| 16 | PFPQPQLPYPQPQL | 4.8 | 2.1 | 14.1 | 0.9 | 5.8 | 3.4 | 1.4 | 1.0 | 3.3 | 1.0 | 2.4 | 0.9 | 1.4 | 0.8 | 1.3 | 0.9 | 0.9 | 1.2 |
| 17 | PQLPYPQPQLPYPQ | 1.4 | 4.1 | 20.6 | 0.9 | 14.8 | 6.0 | 1.0 | 1.1 | 4.7 | 1.0 | 5.9 | 1.1 | 1.0 | 1.5 | 2.2 | 1.4 | 0.5 | 0.8 |
| 18 | YPQPQLPYPQPQLP | 1.8 | 3.9 | 6.4 | 1.8 | 6.0 | 1.5 | 0.9 | 1.1 | 1.8 | 1.0 | 1.6 | 1.2 | 0.9 | 1.5 | 1.3 | 0.7 | 0.5 | 1.0 |
| 21 | PQPFRPQQPYPQSQ | 1.0 | 2.4 | 2.8 | 0.8 | 21.8 | 0.9 | 1.0 | 1.1 | 1.3 | 1.0 | 6.5 | 0.9 | 1.4 | 0.7 | 1.0 | 0.8 | 1.0 | 0.8 |
| 36 | DVVLQQHSIAYGSS | 0.9 | 3.0 | 0.9 | 0.9 | 1.3 | 0.6 | 1.0 | 0.6 | 0.9 | 1.0 | 1.0 | 0.7 | 1.3 | 1.3 | 1.2 | 1.0 | 0.6 | 0.8 |
| 46 | RCQAIHNVVHAIIL | 9.3 | 2.6 | 2.1 | 0.9 | 0.6 | 0.7 | 1.4 | 0.6 | 1.1 | 1.0 | 0.9 | 0.4 | 1.3 | 1.0 | 1.3 | 0.9 | 0.6 | 1.0 |
| 47 | IHNVVHAIILHQQQ | 3.2 | 2.6 | 1.4 | 0.9 | 0.7 | 1.6 | 1.1 | 0.0 | 0.9 | 1.1 | 0.9 | 0.7 | 3.3 | 0.6 | 1.4 | 0.9 | 0.8 | 1.1 |
| 83 | LQLQPFPQPELPYP | 41.3 | 2.8 | 213.3 | 10.8 | 97.0 | 23.2 | 4.3 | 1.0 | 34.2 | 0.9 | 43.7 | 2.2 | 1.0 | 1.0 | 2.8 | 0.8 | 1.5 | 1.0 |
| 84 | PFPQPELPYPQPQL | 16.7 | 3.5 | 155.4 | 1.3 | 91.3 | 17.6 | 3.2 | 1.0 | 31.9 | 1.0 | 40.9 | 1.5 | 0.9 | 1.0 | 2.1 | 1.0 | 1.5 | 1.0 |
| 85 | PELPYPQPELPYPQ | 45.0 | 2.6 | 276.5 | 2.1 | 157.4 | 20.5 | 4.2 | 1.0 | 43.4 | 1.0 | 41.4 | 2.0 | 1.4 | 0.6 | 5.8 | 1.4 | 2.8 | 1.2 |
| 86 | YPQPELPYPQPQLP | 25.4 | 2.7 | 156.1 | 2.5 | 69.1 | 33.3 | 3.0 | 0.8 | 24.9 | 1.0 | 28.9 | 2.7 | 0.8 | 0.9 | 2.4 | 0.9 | 1.2 | 0.9 |
| 89 | PQPFRPEQPYPQSQ | 4.6 | 0.9 | 16.0 | 1.3 | 105.7 | 0.9 | 1.7 | 1.4 | 2.2 | 1.1 | 42.0 | 1.0 | 1.2 | 1.1 | 1.1 | 1.1 | 1.7 | 1.0 |
| 91 | SQPQYSQPEQPISQ | 0.9 | 1.4 | 0.7 | 0.9 | 19.4 | 1.4 | 1.0 | 1.1 | 0.9 | 1.0 | 7.4 | 1.2 | 0.8 | 1.0 | 1.2 | 1.1 | 0.8 | 1.1 |
Plasma was pooled from whole blood stimulations from all six patients in Cohort 1. Note that only peptides 1 to 92 were assessed for individual patients; peptides that were deemed active for IL‐2, IFN‐γ, or IL‐10, but were not reassessed with individual plasmas include: 95 (QQQEEQILEQILQQ), 105 (TYQLVQQLCCEQLW), 111 (QEQPLSEVSFEQPQ), 120 (ELPQFEEIRNLALE), 124 (PQPF‐Cit‐PQQPYPQSQ), 131 (PEQS‐Cit‐CQAIHNVVH), 139 (QQQQQQQQQ‐hCit‐QQQQ), 142 (QPELPYPQPQPF‐Cit‐P), 144 (PQPF‐Cit‐PEQPYPQSQ).
Amino acid sequences related to known HLA‐DQ2.5‐restricted epitopes are underlined: DQ2.5‐glia‐α1a (PFPQPQLPY), DQ2.5‐glia‐α1b (PYPQPQLPY), DQ2.5‐glia‐α2 (PQPQLPYPQ), and DQ2.5‐glia‐α3 (FRPQQPYPQ), DQ2.2‐glia‐α2 (QYSQPQQPI), where Q is preferentially deamidated by TG2 and represented by E.